Dashboard
Manage Tickers

VERAVera Therapeutics, Inc.

Nasdaq veratx.com


$ 38.28 $ 1.09 (2.93 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 38.29
$ 37.74
$ 38.07 x 100
-- x --
$ 37.74 - $ 38.91
$ 9.24 - $ 50.78
279,268
na
2.1B
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-27-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-28-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-25-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 06-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-vera-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:17:38

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 ...

cantor-fitzgerald-reiterates-overweight-on-vera-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/06/2024 13:52:55

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 ...

vaxcyte-shoals-technologies-polestar-automotive-applied-optoelectronics-and-other-big-stocks-moving-higher-on-tuesday
Vaxcyte, Shoals Technologies, Polestar Aut...
09/03/2024 14:47:56

jp-morgan-maintains-overweight-on-vera-therapeutics-raises-price-target-to-72
JP Morgan Maintains Overweight on Vera The...
09/03/2024 13:54:40

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...

jp-morgan-maintains-overweight-on-vera-therapeutics-lowers-price-target-to-62
JP Morgan Maintains Overweight on Vera The...
08/13/2024 12:39:25

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...

vera-therapeutics-q2-eps-062-misses-056-estimate
Vera Therapeutics Q2 EPS $(0.62) Misses $(...
08/08/2024 12:46:02

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $...

vera-therapeutics-appoints-david-johnson-as-coo
Vera Therapeutics Appoints David Johnson A...
07/01/2024 12:09:01

stericycle-marinemax-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-monday
Stericycle, MarineMax, Agios Pharmaceutica...
06/03/2024 14:39:44

wall-street-snaps-five-week-winning-streak-economic-growth-slows-inflation-holds-steady-in-april-this-week-in-the-market
Wall Street Snaps Five-Week Winning Streak...
05/31/2024 20:15:22

U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home pri...

jp-morgan-maintains-overweight-on-vera-therapeutics-raises-price-target-to-65
JP Morgan Maintains Overweight on Vera The...
05/31/2024 17:20:26

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...

nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the-ai-chipmaker
Nvidia Is Up 186% From A Year Ago, Yet The...
05/29/2024 21:56:11

NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance r...

vera-therapeutics-receives-fda-breakthrough-therapy-designation-for-atacicept-in-igan
Vera Therapeutics Receives FDA Breakthroug...
05/28/2024 12:05:29

reported-saturday-vera-therapeutics-presented-72-week-egfr-stabilization-and-rapid-hematuria-improvement-in-phase-2b-origin-study-of-atacicept-in-igan-at-the-61st-european-renal-association-congress
Reported Saturday, Vera Therapeutics Prese...
05/28/2024 07:38:12

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improveme...

raymond-james-maintains-strong-buy-on-vera-therapeutics-raises-price-target-to-68
Raymond James Maintains Strong Buy on Vera...
05/10/2024 17:10:32

Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price targ...

update--vera-therapeutics-q1-eps-056-up-from-080-yoy
UPDATE: Vera Therapeutics Q1 EPS $(0.56) ...
05/09/2024 12:59:01

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(...

vertexs-alpine-acquisition-unpacking-analyst-predictions-on-povetacicepts-potential-impact
Vertex's Alpine Acquisition: Unpacking Ana...
04/11/2024 18:47:33

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...

why-rallybio-shares-are-trading-higher-by-around-78-here-are-20-stocks-moving-premarket
Why Rallybio Shares Are Trading Higher By ...
04/11/2024 10:14:41

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collabo...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

Core News & Articles
Watching Vera Therapeutics; Traders Circul...
04/10/2024 16:53:54

guggenheim-reiterates-buy-on-vera-therapeutics-maintains-56-price-target
Guggenheim Reiterates Buy on Vera Therapeu...
04/05/2024 14:29:40

Guggenheim analyst Vamil Divan reiterates Vera Therapeutics (NASDAQ:VERA) with a Buy and maintains $56 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION